Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada; Research Center, CHU Ste-Justine, Montreal, Quebec, Canada.
Research Center, CHU Ste-Justine, Montreal, Quebec, Canada.
PLoS One. 2014 Apr 4;9(4):e93870. doi: 10.1371/journal.pone.0093870. eCollection 2014.
We evaluated the potential and the validity of the Quebec Pregnancy Cohort (QPC) as a research tool in perinatal pharmacoepidemiology.
The QPC was built by linking four administrative databases: RAMQ (medical and pharmaceutical data), Med-Echo (hospitalizations), ISQ (births/deaths), and MELS (Ministry of Education data). A self-administered questionnaire was sent to a random sample of women to collect lifestyle information. The QPC includes data on all pregnancies of women covered by the Quebec provincial prescription drug insurance between 1998 and 2008. Date of entry in the QPC is the first day of pregnancy, and women are followed during and after pregnancy; children are followed after birth up until 2009. The prevalence of prescribed medications before, during and after pregnancy was compared between time-window. Pregnancy outcomes were also estimated among pregnancies ending with a live born infant.
The QPC included 289,688 pregnancies of 186,165 women. Among them, 167,398 ended with a delivery representing 19.4% of all deliveries occurring in the Province of Quebec between 1998-2009. The total frequency of abortions was 35.9% in the QPC comparable to the 36.4% observed in the Province of Quebec. The prevalence of prescribed medication use was 74.6%, 59.0%, and 79.6% before, during and after pregnancy, respectively. Although there was a statistically significant decrease in the proportion of use once the pregnancy was diagnosed (p<.01), post-pregnancy prescribed medication use returned above the pre-pregnancy level. The prevalence of pregnancy outcomes found in the QPC were similar to those observed in the Province of Quebec.
The QPC is an excellent tool for the study of the risk and benefit of drug use during the perinatal period. This cohort has the advantage of including a validated date of beginning of pregnancy giving the possibility of assigning the exact gestational age at the time of maternal exposure.
我们评估了魁北克妊娠队列(QPC)作为围产期药物流行病学研究工具的潜力和有效性。
QPC 通过链接四个行政数据库构建而成:RAMQ(医疗和药物数据)、Med-Echo(住院)、ISQ(出生/死亡)和 MELS(教育部数据)。向随机抽取的女性发送了一份自我管理问卷,以收集生活方式信息。QPC 包含了 1998 年至 2008 年期间覆盖魁北克省处方药保险的所有女性的妊娠数据。QPC 的入组日期为妊娠第一天,女性在妊娠期间和妊娠后都被随访;孩子在出生后至 2009 年期间也被随访。比较了不同时间窗口内妊娠前、妊娠中和妊娠后的处方药物使用率。还估计了在活产婴儿分娩的妊娠结局。
QPC 共纳入 289688 例妊娠,涉及 186165 名女性。其中,167398 例妊娠以分娩结束,占 1998 年至 2009 年期间魁北克省所有分娩的 19.4%。QPC 中的堕胎总频率为 35.9%,与魁北克省观察到的 36.4%相当。妊娠前、妊娠中和妊娠后的处方药物使用率分别为 74.6%、59.0%和 79.6%。尽管一旦确诊妊娠,药物使用率的比例有统计学意义的下降(p<.01),但妊娠后处方药物使用率恢复到妊娠前水平之上。QPC 中观察到的妊娠结局与魁北克省观察到的相似。
QPC 是研究围产期药物使用风险和益处的绝佳工具。该队列的优势在于包含了一个经过验证的妊娠开始日期,能够在母体暴露时确定确切的孕龄。